- Brenntag and Insempra signed an exclusive global distribution agreement for Insempra's Omega-7 biolipid (CosVivet ActiLipid O7).
- CosVivet ActiLipid O7 is a precision‑fermented, oil‑soluble Omega‑7 biolipid positioned as an alternative to sea buckthorn and macadamia oils.
- The ingredient targets sensitive skin care formulations, offering moisturization, high omega‑7 content and compatibility with lipophilic raw materials.
- Launch and presentation are scheduled at in‑cosmetics Global in Paris in April 2026; this is the first of multiple products planned under the collaboration.
Deal and product
Brenntag signed an exclusive global distribution agreement to commercialize Insempra's Omega‑7 biolipid, marketed as CosVivet ActiLipid O7, the first product under a broader strategic collaboration.
Technical and manufacturing
CosVivet ActiLipid O7 is produced via precision/advanced fermentation; it is a clear yellow, oil‑soluble liquid with minimal odour, high thermal stability and a strong environmental profile, positioned as an alternative to variable natural oils like sea buckthorn and macadamia.
Performance and formulation
With high omega‑7 content, the biolipid is designed to support skin barrier, moisturization and elasticity, suited for sensitive or delicate skin; it offers multifunctional performance and a refined sensory profile—silky, lightweight, non‑greasy feel, easy spreadability—and is compatible with lipophilic raw materials with minimal impact on odour and colour in finished formulations.
Launch and availability
The ingredient will be launched and presented at in‑cosmetics Global in Paris in April 2026 (presentation scheduled 15 April, 13:45–14:15 at the Sustainability Zone Theatre) and will be offered exclusively by Brenntag Beauty & Personal Care globally.
